<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00685880</url>
  </required_header>
  <id_info>
    <org_study_id>07-006348</org_study_id>
    <nct_id>NCT00685880</nct_id>
  </id_info>
  <brief_title>Prolotherapy Versus Steroids for Thumb Carpo-metacarpal Joint Arthritis</brief_title>
  <official_title>Randomized, Double Blind Comparison Trial of Prolotherapy (Dextrose) Compared to Corticosteroid Injection for the Treatment of Symptomatic Thumb Carpo-metacarpal Joint Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arthritis of the base of the thumb is a common debilitating problem. It is believed that
      laxity (loosening) of the joint leads to worsening arthritis in this joint. This can be
      treated by securing the joint surgically or symptoms can be treated with hand therapy and/or
      injection of corticosteroids. Recently prolotherapy (sugar water) has been shown to decrease
      looseness of joints and also be helpful for hand and knee arthritis. We hypothesize that
      prolotherapy injections for thumb arthritis will be equally or more beneficial to the
      patients than steroids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dextrose prolotherapy has been shown to decrease anterior cruciate ligament (ACL) laxity and
      decrease knee joint pain. Similar to ACL laxity leading to knee osteoarthritis, laxity of the
      &quot;beak&quot; ligament can lead to worsening thumb CMC osteoarthritis. We hypothesize that dextrose
      intra-articular prolotherapy will have similar results in treating the pain and instability
      related to symptomatic thumb CMC osteoarthritis. This will be a prospective randomized double
      blind comparison study comparing Celestone to Dextrose intra-articular injections as adjuncts
      to hand therapy for the treatment of symptomatic thumb CMC osteoarthritis. Twenty patients
      will be randomized to each treatment arm to provide enough power to show a 20% change in
      visual analogue scale (VAS) for pain to be significant. We will utilize the ultrasound guided
      injection protocol described by the co-investigators for both treatment arms to ensure proper
      placement of the respective solutions. We will measure various grip strengths, and VAS pain
      scales prior to the first injection, prior to the second injection at 6 weeks and at the
      final visit at 6 months. A telephone follow-up with pain scale will be administered at 3
      months. A Quick Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire measuring
      upper extremity functional impairment will be obtained at initial and final visits.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to recruit adequate numbers of patients
  </why_stopped>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Decreased Pain Score &gt;20%</measure>
    <time_frame>baseline, 6 month follow-up</time_frame>
    <description>Pain was measured on a 10 point visual analogue scale (VAS), with 0 meaning no pain, and 10 meaning extreme pain.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Thumb Carpometacarpal Joint Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Prolotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to this arm will receive injection(s) of 10% dextrose solution in the affected thumb joint.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticosteroid Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prolotherapy (10% dextrose solution)</intervention_name>
    <description>Dextrose diluted with sterile water.</description>
    <arm_group_label>Prolotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betamethasone</intervention_name>
    <description>CELESTONE® SOLUSPAN® * (betamethasone injectable suspension) Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Subjects will receive a 0.25 to 0.5 mL Celestone Soluspan injection.</description>
    <arm_group_label>Corticosteroid Group</arm_group_label>
    <other_name>Celestone Soluspan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;45

          -  Ability to make follow-up visits over the 6 month protocol

          -  Ability to give informed consent

          -  Eaton grade 2-3 thumb carpo-metacarpal joint osteoarthritis with pain over 3/10 on
             visual analogue scale with symptoms present greater then 6 months.

        Exclusion Criteria:

          -  Recent trauma to the hand or wrist or fractures eeen on radiographs

          -  Eaton grade 1, or 4 joints affected

          -  Metabolic bone disease

          -  Recent systemic or localized infection (within last 2 weeks)

          -  History of rheumatologic disease

          -  Allergies to injected solutions

          -  Thumb carpo-metacarpal joint injections in the prior 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Gruba, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic Physical Medicine &amp; Rehabilitation Residency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <reference>
    <citation>Asakawa H, Miyagawa J, Higashiyama S, Goishi K, Hanafusa T, Kuwajima M, Taniguchi N, Matsuzawa Y. High glucose and hyperosmolarity increase heparin-binding epidermal growth factor-like growth factor (HB-EGF) production in cultured human aortic endothelial cells. Cell Biochem Funct. 1996 Sep;14(3):181-6.</citation>
    <PMID>8888571</PMID>
  </reference>
  <reference>
    <citation>Berggren M, Joost-Davidsson A, Lindstrand J, Nylander G, Povlsen B. Reduction in the need for operation after conservative treatment of osteoarthritis of the first carpometacarpal joint: a seven year prospective study. Scand J Plast Reconstr Surg Hand Surg. 2001 Dec;35(4):415-7.</citation>
    <PMID>11878178</PMID>
  </reference>
  <reference>
    <citation>Clarkson MR, Murphy M, Gupta S, Lambe T, Mackenzie HS, Godson C, Martin F, Brady HR. High glucose-altered gene expression in mesangial cells. Actin-regulatory protein gene expression is triggered by oxidative stress and cytoskeletal disassembly. J Biol Chem. 2002 Mar 22;277(12):9707-12. Epub 2002 Jan 9. Erratum in: J Biol Chem 2002 Jun 21;277(25):23100-2.</citation>
    <PMID>11784718</PMID>
  </reference>
  <reference>
    <citation>Dagenais S, Ogunseitan O, Haldeman S, Wooley JR, Newcomb RL. Side effects and adverse events related to intraligamentous injection of sclerosing solutions (prolotherapy) for back and neck pain: A survey of practitioners. Arch Phys Med Rehabil. 2006 Jul;87(7):909-13.</citation>
    <PMID>16813776</PMID>
  </reference>
  <reference>
    <citation>Day CS, Gelberman R, Patel AA, Vogt MT, Ditsios K, Boyer MI. Basal joint osteoarthritis of the thumb: a prospective trial of steroid injection and splinting. J Hand Surg Am. 2004 Mar;29(2):247-51.</citation>
    <PMID>15043897</PMID>
  </reference>
  <reference>
    <citation>Di Paolo S, Gesualdo L, Ranieri E, Grandaliano G, Schena FP. High glucose concentration induces the overexpression of transforming growth factor-beta through the activation of a platelet-derived growth factor loop in human mesangial cells. Am J Pathol. 1996 Dec;149(6):2095-106.</citation>
    <PMID>8952542</PMID>
  </reference>
  <reference>
    <citation>Glickel SZ. Clinical assessment of the thumb trapeziometacarpal joint. Hand Clin. 2001 May;17(2):185-95. Review.</citation>
    <PMID>11478041</PMID>
  </reference>
  <reference>
    <citation>Hackett, G. (1956). Ligament and Tendon Relaxation Treated by Prolotherapy. Springfield, IL, Charles C Thomas.</citation>
  </reference>
  <reference>
    <citation>Han DC, Isono M, Hoffman BB, Ziyadeh FN. High glucose stimulates proliferation and collagen type I synthesis in renal cortical fibroblasts: mediation by autocrine activation of TGF-beta. J Am Soc Nephrol. 1999 Sep;10(9):1891-9.</citation>
    <PMID>10477140</PMID>
  </reference>
  <reference>
    <citation>Jones SC, Saunders HJ, Qi W, Pollock CA. Intermittent high glucose enhances cell growth and collagen synthesis in cultured human tubulointerstitial cells. Diabetologia. 1999 Sep;42(9):1113-9.</citation>
    <PMID>10447524</PMID>
  </reference>
  <reference>
    <citation>Joshi R. Intraarticular corticosteroid injection for first carpometacarpal osteoarthritis. J Rheumatol. 2005 Jul;32(7):1305-6.</citation>
    <PMID>15996069</PMID>
  </reference>
  <reference>
    <citation>Liu YK, Tipton CM, Matthes RD, Bedford TG, Maynard JA, Walmer HC. An in situ study of the influence of a sclerosing solution in rabbit medial collateral ligaments and its junction strength. Connect Tissue Res. 1983;11(2-3):95-102.</citation>
    <PMID>6224646</PMID>
  </reference>
  <reference>
    <citation>Meenagh GK, Patton J, Kynes C, Wright GD. A randomised controlled trial of intra-articular corticosteroid injection of the carpometacarpal joint of the thumb in osteoarthritis. Ann Rheum Dis. 2004 Oct;63(10):1260-3.</citation>
    <PMID>15361383</PMID>
  </reference>
  <reference>
    <citation>Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, Brady HR. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem. 1999 Feb 26;274(9):5830-4.</citation>
    <PMID>10026205</PMID>
  </reference>
  <reference>
    <citation>Otsuka Y, Mizuta H, Takagi K, Iyama K, Yoshitake Y, Nishikawa K, Suzuki F, Hiraki Y. Requirement of fibroblast growth factor signaling for regeneration of epiphyseal morphology in rabbit full-thickness defects of articular cartilage. Dev Growth Differ. 1997 Apr;39(2):143-56.</citation>
    <PMID>9108328</PMID>
  </reference>
  <reference>
    <citation>Pai S, Talwalkar S, Hayton M. Presentation and management of arthritis affecting the trapezio-metacarpal joint. Acta Orthop Belg. 2006 Jan;72(1):3-10. Review.</citation>
    <PMID>16570886</PMID>
  </reference>
  <reference>
    <citation>Pellegrini VD Jr. Pathomechanics of the thumb trapeziometacarpal joint. Hand Clin. 2001 May;17(2):175-84, vii-viii. Review.</citation>
    <PMID>11478040</PMID>
  </reference>
  <reference>
    <citation>Pugliese G, Pricci F, Locuratolo N, Romeo G, Romano G, Giannini S, Cresci B, Galli G, Rotella CM, Di Mario U. Increased activity of the insulin-like growth factor system in mesangial cells cultured in high glucose conditions. Relation to glucose-enhanced extracellular matrix production. Diabetologia. 1996 Jul;39(7):775-84.</citation>
    <PMID>8817101</PMID>
  </reference>
  <reference>
    <citation>Reeves, K. (2000). Prolotherapy: Basic Science, Clinical Studies, and Technique. Pain Procedures in Clinical Practice. T. A. Lennard. Philadelphia, PA, Hanley and Belfus, INC.: 172-90.</citation>
  </reference>
  <reference>
    <citation>Reeves KD, Hassanein K. Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity. Altern Ther Health Med. 2000 Mar;6(2):68-74, 77-80.</citation>
    <PMID>10710805</PMID>
  </reference>
  <reference>
    <citation>Reeves KD, Hassanein K. Randomized, prospective, placebo-controlled double-blind study of dextrose prolotherapy for osteoarthritic thumb and finger (DIP, PIP, and trapeziometacarpal) joints: evidence of clinical efficacy. J Altern Complement Med. 2000 Aug;6(4):311-20.</citation>
    <PMID>10976977</PMID>
  </reference>
  <reference>
    <citation>Reeves KD, Hassanein KM. Long-term effects of dextrose prolotherapy for anterior cruciate ligament laxity. Altern Ther Health Med. 2003 May-Jun;9(3):58-62.</citation>
    <PMID>12776476</PMID>
  </reference>
  <reference>
    <citation>Roos MD, Han IO, Paterson AJ, Kudlow JE. Role of glucosamine synthesis in the stimulation of TGF-alpha gene transcription by glucose and EGF. Am J Physiol. 1996 Mar;270(3 Pt 1):C803-11.</citation>
    <PMID>8638660</PMID>
  </reference>
  <reference>
    <citation>Swigart CR, Eaton RG, Glickel SZ, Johnson C. Splinting in the treatment of arthritis of the first carpometacarpal joint. J Hand Surg Am. 1999 Jan;24(1):86-91.</citation>
    <PMID>10048521</PMID>
  </reference>
  <reference>
    <citation>van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB. Differential effects of local application of BMP-2 or TGF-beta 1 on both articular cartilage composition and osteophyte formation. Osteoarthritis Cartilage. 1998 Sep;6(5):306-17.</citation>
    <PMID>10197165</PMID>
  </reference>
  <reference>
    <citation>Wakitani S, Imoto K, Kimura T, Ochi T, Matsumoto K, Nakamura T. Hepatocyte growth factor facilitates cartilage repair. Full thickness articular cartilage defect studied in rabbit knees. Acta Orthop Scand. 1997 Oct;68(5):474-80.</citation>
    <PMID>9385250</PMID>
  </reference>
  <reference>
    <citation>Woo SL, Hildebrand K, Watanabe N, Fenwick JA, Papageorgiou CD, Wang JH. Tissue engineering of ligament and tendon healing. Clin Orthop Relat Res. 1999 Oct;(367 Suppl):S312-23. Review.</citation>
    <PMID>10546655</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Niu J, Kelly-Hayes M, Chaisson CE, Aliabadi P, Felson DT. Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: The Framingham Study. Am J Epidemiol. 2002 Dec 1;156(11):1021-7.</citation>
    <PMID>12446258</PMID>
  </reference>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2008</study_first_posted>
  <results_first_submitted>July 27, 2012</results_first_submitted>
  <results_first_submitted_qc>July 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 30, 2012</results_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2012</last_update_posted>
  <responsible_party>
    <name_title>Michael Joseph Gruba M.D.</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>thumb carpo metacarpal joint osteoarthritis</keyword>
  <keyword>prolotherapy</keyword>
  <keyword>intra articular steroid</keyword>
  <keyword>hand therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Betamethasone acetate phosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the pool of referrals to the Mayo Hand Clinic who are interested in receiving an injection for their pain, agree to comply with the standardized hand therapy program, meet the inclusion/exclusion criteria and are able to make the scheduled follow-up visits from Mayo 2008 to July 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Prolotherapy Group</title>
          <description>Subjects randomized to this arm will receive injection(s) of 10% dextrose solution in the affected thumb joint.</description>
        </group>
        <group group_id="P2">
          <title>Corticosteroid Group</title>
          <description>Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prolotherapy Group</title>
          <description>Subjects randomized to this arm will receive injection(s) of 10% dextrose solution in the affected thumb joint.</description>
        </group>
        <group group_id="B2">
          <title>Corticosteroid Group</title>
          <description>Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Decreased Pain Score &gt;20%</title>
        <description>Pain was measured on a 10 point visual analogue scale (VAS), with 0 meaning no pain, and 10 meaning extreme pain.</description>
        <time_frame>baseline, 6 month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prolotherapy Group</title>
            <description>Subjects randomized to this arm will receive injection(s) of 10% dextrose solution in the affected thumb joint.</description>
          </group>
          <group group_id="O2">
            <title>Corticosteroid Group</title>
            <description>Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decreased Pain Score &gt;20%</title>
          <description>Pain was measured on a 10 point visual analogue scale (VAS), with 0 meaning no pain, and 10 meaning extreme pain.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects will be followed for adverse events for six months following the intervention.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prolotherapy Group</title>
          <description>Subjects randomized to this arm will receive injection(s) of 10% dextrose solution in the affected thumb joint.</description>
        </group>
        <group group_id="E2">
          <title>Corticosteroid Group</title>
          <description>Subjects randomized to this arm will receive injection(s) of betamethasone solution in the affected thumb joint.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to low enrollment; no subject data was analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jeffrey S. Brault</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-1643</phone>
      <email>brault.jeffrey@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

